Other News To Note
Wednesday, October 2, 2013
• Biotie Therapies Corp., of Turku, Finland, said that its partner H. Lundbeck A/S, of Copenhagen, has brought Selincro (nalmefene) to the market in Italy, triggering a €2 million (US$1.9 million) milestone to Biotie.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.